USFDA completes inspection of Lupin's Goa plant with 2 observations
Drug firm Lupin on Friday said the US health regulator has completed inspection of its Goa facility and made two key observations.
In a BSE filing, Lupin said, "The observations are procedural in nature and the company is confident of addressing them satisfactorily."
Disclaimer: No Business Standard Journalist was involved in creation of this content